Insight Molecular Diagnostics Inc.

For the period ended Mar 26, 2026. Filed Mar 26, 2026.

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

Mar 26, 2026 · Filed Mar 26, 2026

Use the contents to explore the available documents and sections.

IMDX$2.49+1.2%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

EX-99.1 · (In thousands, except per share data)

(In thousands, except per share data)

	Three Months Ended December 31,		Years Ended December 31,
	2025	2024	2025	2024
Net revenue	$1,139	$1,486	$4,055	$1,881
Cost of revenues	643	869	1,750	1,053
Cost of revenues – amortization of acquired intangibles	—	22	7	88
Gross profit	496	595	2,298	740
Operating expenses:
Research and development	5,829	2,257	15,900	9,839
Sales and marketing	2,291	1,202	6,343	3,944
General and administrative	2,326	2,559	10,633	10,204
Change in fair value of contingent consideration	(1,115)	(13,696)	5,946	(4,275)
Impairment losses	14,600	41,900	14,600	41,900
Impairment loss on held for sale assets	—	—	—	169
Total operating expenses	23,931	34,222	53,422	61,781
Loss from operations	(23,435)	(33,627)	(51,124)	(61,041)
Other (expenses) income:
Interest expense	(26)	(30)	(109)	(84)
Other income, net	506	146	1,011	462
Total other income, net	480	116	902	378
Loss before income taxes	(22,955)	(33,511)	(50,222)	(60,663)
Income taxes	—	—	—	—
Net loss	$(22,955)	$(33,511)	$(50,222)	$(60,663)
Net loss per share:
Net loss attributable to common stockholders - basic and diluted	$(22,955)	$(33,511)	$(50,222)	$(60,926)
Net loss attributable to common stockholders per share - basic and diluted	$(0.72)	$(1.93)	$(1.65)	$(4.66)
Weighted average shares outstanding - basic and diluted	32,065	17,382	30,476	13,071

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.